Skip to main navigation Skip to search Skip to main content

Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress

  • Gethin R. Ellis*
  • , Angus K. Nightingale
  • , Daniel J. Blackman
  • , Richard A. Anderson
  • , Catherine Mumford
  • , Graham Timmins
  • , Derek Lang
  • , Simon K. Jackson
  • , Michael D. Penney
  • , Malcolm J. Lewis
  • , Michael P. Frenneaux
  • , Jayne Morris-Thurgood
  • *Corresponding author for this work
  • Cwm Taf Morgannwg University Health Board
  • Cardiff University
  • Northampton General Hospital NHS Trust
  • Aneurin Bevan Health Board

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)193-199
Number of pages0
JournalEuropean Journal of Heart Failure
Volume4
Issue number2
DOIs
Publication statusPublished - 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • heart failure
  • angiotensin
  • drugs
  • endothelium
  • free radicals

Cite this